ABOUT
GEMATRIA PRODUCTS...
MISSION
STATEMENT
We
Help People Feel Better.
OBJECTIVES:
1.
To create and provide to the world the most technologically
advanced and superior health promoting nutritional supplements
available.
2.
To use the highest integrity, the best intentions, and
the customers' health and well-being in the forefront
of all our corporate actions.
Gematria
Products Inc. was incorporated on July 10, 1996 and
since has been diligently working on the R&D of
a wide range of laser enhanced nutritional supplements
that are largely amino acid, nucleotide, and vitamin
based. We currently have 29 products in our product
repertoire.
To
understand the beginnings of Gematria Products Inc.
and our patented laser enhancement process, it is important
to begin with Dr. Todd Ovokaitys, CEO, MD (pulmonary
& critical care specialist), and product formulator
and to discuss his work with the laser acoustic resonance
of molecular structure.
As
to Dr. Todd's (as he is called) formal academic background,
he received BA and MD degrees from Johns Hopkins University
after acceptance into an accelerated integrated medical
training program. Following this training he completed
an Internship, Residency, and Chief Medical Residency
in the Georgetown University Hospital System. This was
followed by a two year Fellowship in Pulmonary and Intensive
Care Medicine, also at Georgetown University Hospital.
At
Georgetown, Dr. Todd participated in formal studies
of T cell immune function after harvesting lymphocytes
from the lung via fiberoptic bronchoscopy. In addition,
this training involved intensive care of many persons
afflicted with HIV infection, as the lung is a common
target following the immunologic breakdown of this condition.
Aware
of the extreme limitations of treating HIV through ordinary
conventional means, I began a search for less intrusive
solutions. The concept of using the subtle differences
of genetic organization between the viral and human
genomes was the launch point for exploring new avenues
of molecular resonance technologies. In concept, the
slight differences of resonance signatures between the
viral and human genomes could be used to selectively
target and eliminate infected parts of cells leaving
uninfected normal cells unharmed.
After
studying the background work on the effects of electromagnetic
radiation on living systems, a colleague was located
with the expertise to design and build a fundamentally
new laser electromagnetic resonance technology. Scott
Strachan, a Scottish physicist, electrical, and chemical
engineer took the basic concepts and reduced them to
a functional technology within 6 weeks. Among his accomplishments
are being an inventor of real time ultrasound and being
the recipient of the Enterprise Scotland Award from
Prince Charles for development of highly precise laser
measurement instruments.
This
new laser optical technology has been patented worldwide
as U.S. 6064500 and worldwide patent WO09722022A1.
This
invention is formally described as a "holographic
temporal displacement prism for the non-fringing phase
conjugate interference of light." The new wave
structure of light produced has a range of physical
properties that transcends several of the usual limits
of laser-molecular and laser-tissue interactions. When
ordinary laser light in the visible spectrum interacts
with tissue there is intense scattering such that a
coherent signal cannot penetrate more than 5mm. Sparse
constructive nodes are ultra-brief wave summation signals
that spark in and out of existence deeply in tissue
or an otherwise scattering medium, with 6-20cm projection
even through bone predicted. The duration of the pulse
is just long enough to excite specific desired molecular
stimulation, yet brief enough not to nonspecifically
heat target molecular structures.
Global
applications patents have been submitted for "The
Use of Sparse Constructive Nodes (of electromagnetic
energy) for the Selective Modulation of Cell Surface
Chemistry." This general applications patent covers
the use of the laser technology to activate and enhance
desired cell chemistries in vitro and in vivo. In addition
this patent also covers the use of the laser to activate
or homogenize the state of nutrients or pharmaceuticals
to increase the specific desired biological activity.
In
addition to this work, a recent randomized prospective,
placebo controlled clinical study suggests the potency
and efficacy of laser-enhanced betaine (trimethylglycine)
in our HeartGems product. Over a three-month protocol
of increasing doses of an activated betaine and cofactor
formula, the study showed the following:
